Sign in

Daniel Tassé

Chief Executive Officer at DBV Technologies
Board
Since November 2018
Age
64 years
Education
Earned a Bachelor of Science (B.Sc.) in Biochemistry from Université de Montréal.
Tenure
Joined DBVT as Chief Executive Officer in November 2018 and became a board member in March 2019.

Also at DBV Technologies

DPM
Dr. Pharis Mohideen
Chief Medical Officer
VB
Virginie Boucinha
Chief Financial Officer

About

Daniel Tassé is a seasoned executive with extensive experience in the biotechnology and pharmaceutical sectors, currently serving as the Chief Executive Officer at DBVT since November 2018.

With a strong educational background that includes a Bachelor of Science in Biochemistry from Université de Montréal, he has built a career marked by strategic leadership and a commitment to advancing clinical programs.

Beyond his role at DBVT, he has held various leadership positions and board memberships at several notable companies, reflecting a robust track record in corporate governance and operational excellence.

$DBVT Performance Under Daniel Tassé

Past Roles

OrganizationRoleDate RangeDetails
Indivior plc Board Director (Lead Independent Director, Interim Chair, Audit Committee Chair) 2013 – 2021 N/A
HLS Therapeutics Board of Directors 2018 – 2019 N/A
Bellerophon Therapeutics, Inc. Board of Directors 2014 – 2019 N/A
Alcresta Therapeutics, Inc. Chairman & Chief Executive Officer Mar 2016 – Nov 2018 N/A
Ikaria, Inc. Chairman & Chief Executive Officer Jan 2008 – Apr 2015 Acquired by Mallinckrodt Pharmaceuticals in Apr 2015

External Roles

OrganizationRoleDate RangeDetails
Autous Independent Director Appointed April 2024 Nasdaq-listed company
Regenxbio Inc. Board Director & Compensation Committee Chair Since 2016 N/A

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary $600,000 Annual Fixed compensation for the CEO
Option Awards $1,084,783 At grant dateAggregate grant date fair value computed in accordance with ASC Topic 718
Non-Equity Incentive Plan Compensation $600,000 Contingent on performance (achieved 106% of objectives, approved Jan 16, 2024) Converted from euros using the BCE exchange rate
All Other Compensation $119,703 As applicableIncludes benefit plan contributions ($50,750 ), life insurance premiums ($37,457 ), tax gross-up payments ($30,512 ), and commuting expenses ($984 )

Performance Compensation

Data from  FY 2023

Performance Compensation

Performance Metrics and Targets

MetricBase PointsAdditional PointsTotal Points
Viaskin Peanut – VITESSE clinical study progress 64 33 97
Viaskin Peanut – BLA file preparation 64 33 97
Pipeline Development – Mag1c program 21 7 28
Pipeline Development – Ongoing preclinical/clinical studies 21 7 28
Quarterly Cash Burn Targets 15 8 23
Operating Targets 15 8 23

Total Base Points: 100
Total Additional Points: 48

Achievement

Achieved 106% of the performance criteria (determined by the Board on January 16, 2024).

Stock Option Grant (Performance-Linked)

  • Grant Date: November 20, 2023
  • Number of Options: 809,672
  • Exercise Price: €2.00
  • Vesting Schedule: 4-year staggered vesting; 25% vesting each anniversary; options exercisable until November 20, 2033
  • Grant Date Fair Value: €1,631,372

Additional Performance Component

  • Tax Equalization Payment: $28,522

Severance Conditions (Performance Related)

  • Viaskin Peanut approval in a major market
  • EPIT pipeline with three ongoing clinical trials
  • Six months cash runway as of termination date